BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers

WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell engaging (TCE) antibody and the option of three additional...

January 05, 2023 | News

Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program

Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug co...

January 04, 2023 | News

Aptamer Group’s discovery platform is enabling new solutions across the life sciences.

How is success in the discovery of small molecule ligands increased with the Optimer platform? The Optimer platform incorporates three se...

January 04, 2023 | News

Biocytogen and Hansoh Pharma Announce an Antibody License Agreement

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery a...

January 03, 2023 | News

Merck Announces Collaboration With Mersana Therapeutics to Develop Novel Immunostimulatory Antibody-Drug Conjugates

Collaboration complements Merck’s internal expertise and in-house ADC approach Companies focused on discovering novel STING-agonist ADCs for up to...

December 23, 2022 | News

Pictor announces important COVID-19 trial to map immunity profile of New Zealanders

Pictor, a global leader in immunodiagnostics, today announced an important research project – the Pictor Antibody Clinical Trial (PACT-19) – wh...

December 22, 2022 | News

Genome Insight Develops ‘StreamSeq’ Technology for High-speed Whole Genome Analysis

Genome Insight, a precision medicine whole genome platform company, announced on the 19th that it has been granted a patent for its ‘StreamSeq’...

December 21, 2022 | News

Novavax Announces Pricing of its $150 Million Convertible Debenture Offering

The Notes are currently being offered and sold only to persons who are reasonably qualified institutional purchasers within the meaning of Rule 144A under ...

December 19, 2022 | News

Prenetics Acquires ACT Genomics

Acquisition to bring germline and somatic testing, cell-free DNA-based (liquid biopsy), and tissue-genomic profiling onto a single platform Cancer genom...

December 16, 2022 | News

Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming to Create New Therapies for Neurodegenerative Diseases

Washington University is world leading in research on prevention, diagnosis, biomarkers and treatment of neurodegenerative diseases. The two organizations ...

December 15, 2022 | News

Bio Elpida Acquisition Brings GMP Fill and Finish Capacity to Polyplus

“Bio Elpida is certified by the French Health Authorities (ANSM) as a Pharmaceutical Company to manufacture Active Pharmaceutical Ingredients and Adv...

December 15, 2022 | News

Over £175 million for cutting-edge genomics research to help boost diagnosis treatment for patients

£105 million to speed up diagnosis of rare genetic diseases in newborns, potentially resulting in life-saving interventions for thousands of babies...

December 15, 2022 | News

Merck Signs MoU with Synplogen to Accelerate Development and Manufacturing of Viral Vector-based Gene Therapy Applications

Merck’s Millipore® CTDMO Services (Contract Testing, Development and Manufacturing Organization) to streamline viral vector development and pro...

December 14, 2022 | News

Biosion Announces Research Collaboration with ImmunoGen to Create Novel Antibody-Drug Conjugates

Biosion USA, Inc. (Biosion), a global R&D biotechnology company, today announced an exploratory research collaboration to create antibody-drug con...

December 14, 2022 | News

Stay Connected